RVNC—FDA could start missing PDUFA dates especially for an aesthetic product. That the Daxi BLA in glabellar lines probably doesn’t require an FDA advisory panel is helpful in this regard (#msg-153683771). Luckily the company is now well capitalized and has levers to slow burn if need be so I’m comfortable having added at these levels.It’s not entirely luck. The February convertible-debt offering looks pretty smart now.